Patients treated with UBX1325 had a mean change in BCVA of +6.2 ETDRS letters from baseline to 48 weeks (p=0.0037), representing a difference of +5.6 ETDRS letters compared to sham-treated patients (p=0.1198).UBX1325 demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis.Fifty patients completed the 48-week study extension. In the 6 months prior to study enrollment, patients received an average of 4 anti-VEGF injections, with the last anti-VEGF injection occurring 3-6 weeks prior to randomization. At baseline, patients in the study had an average visual acuity of 61.4 ETDRS letters and a CST of approximately 439.6 microns. The BEHOLD study enrolled patients who, despite being on anti-VEGF treatment for at least 6 months, displayed persistent visual acuity deficits and residual retinal fluid. Based on the strong emerging clinical profile of UBX1325, we are planning to move forward with our Phase 2b DME head-to-head study against aflibercept in the second half of 2023.” “UBX1325 is the only treatment candidate in clinical development that targets senescent cells to potentially modify the course of disease, and this therapeutic approach could redefine the standard of care in DME. Achieving sustained improvements in visual acuity and stabilization of retinal structure for almost 1 year after a single injection of UBX1325 is a remarkable result,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “This is a defining moment for the senolytic therapeutic hypothesis and is a pivotal moment for UNITY. In addition, patients treated with UBX1325 maintained stable CST compared to worsening in sham-treated patients. A single injection of UBX1325 treatment led to a statistically significant improvement in vision lasting for the duration of the study (48 weeks), marked by a gain of +6.2 ETDRS letters from baseline, representing a difference of +5.6 ETDRS letters compared to sham-treated patients. (“UNITY”), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced positive results from the long-term follow-up of the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). SOUTH SAN FRANCISCO, Calif., Ap(GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. UNITY to host investor call with retinal expert UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the duration of the study All Rights Reserved.A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity ( BCVA) of +6.2 ETDRS letters from baseline at 48 weeksĪpproximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. Factset: FactSet Research Systems Inc.2019. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Top 10 Mutual Funds Holding UNITY Biotechnology Inc Mutual fund Top 10 Owners of UNITY Biotechnology Inc Stockholder Bought 312.0 Thousand shares of UNITY Biotechnology IncĭIMENSIONAL FUND ADVISORS LP Bought 37.5 Thousand shares of UNITY Biotechnology IncīLACKROCK FUND ADVISORS Bought 36.3 Thousand shares of UNITY Biotechnology Inc Transactions Latest Institutional Activity įIDELITY MANAGEMENT & RESEARCH C.
0 Comments
Leave a Reply. |